Year: 2022
Type: editorial
Abstract: Rising Stars in Drugs Outcomes Research and Policies: 2021A major part of scientific research is carried out by graduate students, postdoctoral researchers, and faculty who do not yet have permanent employment with an institute or company (Bankston et al., 2020).It is important to encourage early career reseachers as the scientific community needs new talents, skills and ideas to continue to flourish (Heggeness et al., 2017).Consequently, they should be supported to become an important part of the current and future scientific community.This group is also considerably more diverse in terms of gender and ethnicity than the rest of the research enterprise (Nikaj et al., 2018).Several universities and other groups have taken initiatives to help these young researchers with the challenges they encounter.Recommendations were proposed for empowerment of early career researchers (Kent et al., 2022) and more support for research in Low and Middle Income Countries (LMICs) is provided by groups like HTAi (Innovation through Health Technology Assessment) and MURIA (Medicine Utilisation in Africa) for greater research into medicine use (Massel et al., 2017).Frontiers' Drugs Outcomes, Research, and Policies explores the evaluation of drugs, advanced therapies and medical devices containing drugs in real life conditions, following their approval by regulatory authorities and access to the market.Comparisons between drugs are increasingly used to assist decision makers in getting the biggest value for money within cost-constrained healthcare budgets.Drug cost are sometimes a small proportion of overall cost of illness but can account for up to 60-80% of total healthcare expenditure in LMICs-much of which is out of pocket.In addition, in high income countries most new medicines are targeted at cancers/orphan diseases at high prices.In these situations, the costs of medicines are a considerable proportion of the total costs of these diseases and are driving increasing medicine expenditure world wide.So these costs need to be carefully managed especially in countries with Universal Health Care.This is where good new young researchers can play a key role going forward.
Source: Frontiers in Pharmacology
Authors: Robert L. Lins, Fariba Ahmadizar, Tanveer Khan
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W4310043938